Aarti Pharmalabs Limited
NSE: AARTIPHARM BSE: AARTIPHARM
Prev Close
900.35
Open Price
904
Volume
266,300
Today Low / High
887.1 / 913.9
52 WK Low / High
551.05 / 949.5
Range
864 - 955
Prev Close
900.1
Open Price
900.15
Volume
7,960
Today Low / High
887.3 / 913.05
52 WK Low / High
521 / 948.8
Range
867 - 959
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 909.3 (target range: 864 - 955), reflecting a change of 8.95 (0.99406%). On the BSE, it is listed at 912.95 (target range: 867 - 959), showing a change of 12.85 (1.42762%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Aarti Pharmalabs Limited Graph
Aarti Pharmalabs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aarti Pharmalabs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 909.30, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 912.95 | 922.08 | 829.87 - 1,014.29 |
931.21 | 744.97 - 1,117.45 | ||
940.34 | 658.24 - 1,222.44 | ||
Bearish Scenario | 912.95 | 903.82 | 813.44 - 994.20 |
894.69 | 715.75 - 1,073.63 | ||
885.56 | 619.89 - 1,151.23 |
Overview of Aarti Pharmalabs Limited
ISIN
INE0LRU01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
436,343
Market Cap
81,661,792,620
Last Dividend
3.5
Official Website
IPO Date
2023-01-30
DCF Diff
-138.48
DCF
857
Financial Ratios Every Investor Needs
Stock Dividend of AARTIPHARM
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2025-02-14 | February 14, 25 | 2.5 | 2.5 | 2025-02-14 | 2025-03-07 | |
2024-07-31 | July 31, 24 | 1 | 1 | 2024-07-31 | 2024-09-02 | |
2024-02-16 | February 16, 24 | 2 | 2 | 2024-02-19 | 2024-03-08 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 2,115.07 Cr | 1,127.88 Cr | 987.20 Cr | 0.4667 | 0.00 Cr | 0.00 Cr | 377.47 Cr | 272.40 Cr | 30.06 | 464.37 Cr | 0.1288 |
2024-03-31 | 1,815.51 Cr | 1,424.71 Cr | 390.80 Cr | 0.2153 | 8.37 Cr | 138.41 Cr | 312.81 Cr | 216.90 Cr | 23.93 | 390.94 Cr | 0.1195 |
2023-03-31 | 1,945.23 Cr | 1,531.36 Cr | 413.87 Cr | 0.2128 | 13.96 Cr | 129.69 Cr | 279.51 Cr | 193.49 Cr | 21.35 | 344.37 Cr | 0.0995 |
2022-03-31 | 1,192.03 Cr | 879.70 Cr | 312.33 Cr | 0.2620 | 0.00 Cr | 1.51 Cr | 164.83 Cr | 122.25 Cr | 13.49 | 197.84 Cr | 0.1026 |
2021-03-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0000 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -0.18 | 0.00 Cr | 0.0000 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 8.65 Cr | 2,906.41 Cr | 916.50 Cr | 1,989.9064 Cr | 413.12 Cr | 404.47 Cr | 587.58 Cr | 1,410.70 Cr | 0.00 Cr | 0.00 Cr | 29.24 Cr | 657.0495 Cr |
2024-03-31 | 23.63 Cr | 2,582.11 Cr | 825.07 Cr | 1,757.0400 Cr | 285.25 Cr | 261.62 Cr | 642.86 Cr | 1,105.45 Cr | 0.00 Cr | 0.00 Cr | 36.78 Cr | 694.3891 Cr |
2023-03-31 | 12.12 Cr | 2,244.02 Cr | 685.54 Cr | 1,558.4866 Cr | 215.31 Cr | 203.19 Cr | 602.04 Cr | 988.57 Cr | 0.00 Cr | 0.00 Cr | -6.03 Cr | 600.6234 Cr |
2022-03-31 | 83.27 Cr | 2,039.90 Cr | 653.42 Cr | 1,386.4778 Cr | 341.40 Cr | 258.13 Cr | 475.45 Cr | 945.31 Cr | 0.00 Cr | -1.00 Cr | 32.23 Cr | 580.6649 Cr |
2021-03-31 | 0.25 Cr | 0.25 Cr | 0.02 Cr | 0.2267 Cr | 0.02 Cr | -0.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0219 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 331.5615 Cr | -413.8977 Cr | 65.4350 Cr | -70.4759 Cr | -16.9012 Cr | 6.7337 Cr | -443.8784 Cr | 272.4048 Cr | 93.8005 Cr | -31.7191 Cr | 55.2790 Cr |
2024-03-31 | 216.3546 Cr | -214.5644 Cr | 9.7235 Cr | 17.5695 Cr | 11.5137 Cr | 23.6349 Cr | -155.6042 Cr | 216.9020 Cr | 49.9934 Cr | -18.1252 Cr | -39.6600 Cr |
2023-03-31 | 250.1154 Cr | -157.8030 Cr | -163.4646 Cr | 130.4585 Cr | -71.1522 Cr | 12.1212 Cr | -119.6569 Cr | 260.7747 Cr | -124.2877 Cr | -18.1252 Cr | -126.6600 Cr |
2022-03-31 | -43.7038 Cr | -138.7389 Cr | 260.3834 Cr | -184.8558 Cr | 83.0234 Cr | 83.2734 Cr | -141.1520 Cr | 155.3804 Cr | 272.3422 Cr | 0.0000 Cr | -55.9920 Cr |
2021-03-31 | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.2500 Cr | 0.0000 Cr | -0.0046 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 563.78 Cr | 278.75 Cr | 285.03 Cr | 0.5056 | 122.81 Cr | 88.34 Cr | 9.75 | 144.54 Cr | 0.1567 |
2024-12-31 | 537.78 Cr | 275.31 Cr | 262.47 Cr | 0.4881 | 105.57 Cr | 73.99 Cr | 8.16 | 133.64 Cr | 0.1376 |
2024-09-30 | 458.03 Cr | 294.19 Cr | 163.84 Cr | 0.3577 | 72.79 Cr | 54.62 Cr | 6.03 | 98.16 Cr | 0.1193 |
2024-06-30 | 555.49 Cr | 397.64 Cr | 157.85 Cr | 0.2842 | 76.29 Cr | 55.45 Cr | 6.12 | 98.68 Cr | 0.0998 |
2024-03-31 | 468.67 Cr | 347.24 Cr | 121.43 Cr | 0.2591 | 98.40 Cr | 65.25 Cr | 7.20 | 119.55 Cr | 0.1392 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 8.65 Cr | 47.56 Cr | 56.21 Cr | 575.40 Cr | 587.58 Cr | 1,322.17 Cr | 1,410.70 Cr | 2,906.41 Cr | 916.50 Cr |
2024-12-31 | 0.00 Cr | 0.00 Cr | 99.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,856.73 Cr |
2024-09-30 | 40.81 Cr | 58.16 Cr | 99.51 Cr | 434.38 Cr | 719.80 Cr | 1,376.67 Cr | 1,228.35 Cr | 2,776.51 Cr | 919.79 Cr |
2024-06-30 | -94.32 Cr | 188.63 Cr | 94.32 Cr | 0.00 Cr | 0.00 Cr | 94.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 23.63 Cr | 70.40 Cr | 94.45 Cr | 519.34 Cr | 642.86 Cr | 1,345.64 Cr | 1,105.45 Cr | 2,582.11 Cr | 825.07 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 88.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-12-31 | 73.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-09-30 | 54.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-06-30 | 55.45 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 65.25 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
No split history data available. |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,674.10 | ₹4,016,634,648,000.00 | ₹810,840.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,889.50 | ₹1,828,948,675,500.00 | ₹57,066.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,367.00 | ₹1,139,544,315,000.00 | ₹121,578.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,308.00 | ₹1,088,360,299,920.00 | ₹365,638.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹995.25 | ₹1,001,450,407,500.00 | ₹364,100.00 |
Mankind Pharma Limited | MANKIND | ₹2,419.00 | ₹998,390,870,440.00 | ₹314,248.00 |
Lupin Limited | LUPIN | ₹1,975.10 | ₹902,059,771,600.00 | ₹294,678.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,186.00 | ₹688,831,172,000.00 | ₹550,961.00 |
Alkem Laboratories Limited | ALKEM | ₹4,870.00 | ₹582,281,550,000.00 | ₹65,749.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,872.30 | ₹528,364,932,300.00 | ₹891,905.00 |
Laurus Labs Limited | LAURUSLABS | ₹775.00 | ₹417,921,075,000.00 | ₹840,385.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Cohance Lifesciences Limited | COHANCE | ₹1,018.95 | ₹389,816,652,802.00 | ₹122,471.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,466.30 | ₹372,006,175,200.00 | ₹298,346.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,658.70 | ₹332,103,534,400.00 | ₹86,616.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,710.90 | ₹277,985,321,100.00 | ₹324,650.00 |
Piramal Enterprises Limited | PEL | ₹1,152.80 | ₹261,314,398,400.00 | ₹110,079.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,638.90 | ₹255,765,095,100.00 | ₹229,621.00 |
Eris Lifesciences Limited | ERIS | ₹1,742.70 | ₹237,350,511,900.00 | ₹113,014.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,112.00 | ₹227,800,000,000.00 | ₹11,413.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹1,004.40 | ₹197,427,877,200.00 | ₹89,538.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,198.90 | ₹190,961,990,900.00 | ₹421,209.00 |
NATCO Pharma Limited | NATCOPHARM | ₹973.40 | ₹174,345,674,000.00 | ₹1,189,397.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,024.10 | ₹153,855,281,970.00 | ₹55,029.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹11,791.00 | ₹151,277,350,900.00 | ₹14,602.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹493.85 | ₹119,829,739,400.00 | ₹256,522.00 |
Procter & Gamble Health Limited | PGHL | ₹5,780.00 | ₹95,944,532,000.00 | ₹5,195.00 |
Shilpa Medicare Limited | SHILPAMED | ₹888.15 | ₹86,852,987,835.00 | ₹29,562.00 |
FDC Limited | FDC | ₹514.20 | ₹83,716,902,000.00 | ₹692,435.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹909.90 | ₹82,468,440,738.00 | ₹250,444.00 |
Strides Pharma Science Limited | STAR | ₹874.65 | ₹80,610,105,555.00 | ₹240,574.00 |
Suven Life Sciences Limited | SUVEN | ₹267.86 | ₹58,413,301,640.00 | ₹338,303.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹157.16 | ₹51,001,877,520.00 | ₹171,154.00 |
Innova Captab Limited | INNOVACAP | ₹851.60 | ₹48,732,750,388.00 | ₹19,540.00 |
Sequent Scientific Limited | SEQUENT | ₹184.54 | ₹46,191,284,700.00 | ₹237,353.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹491.50 | ₹44,859,205,000.00 | ₹357,856.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,679.80 | ₹44,321,212,200.00 | ₹79,580.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹599.60 | ₹42,215,317,680.00 | ₹93,851.00 |
Hikal Limited | HIKAL | ₹341.85 | ₹42,150,446,850.00 | ₹104,423.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹740.00 | ₹37,532,134,000.00 | ₹43,490.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹64.45 | ₹35,315,635,300.00 | ₹2,567,496.00 |
Gufic Biosciences Limited | GUFICBIO | ₹344.10 | ₹34,505,659,800.00 | ₹14,189.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹633.65 | ₹30,512,148,450.00 | ₹58,137.00 |
Alembic Limited | ALEMBICLTD | ₹118.80 | ₹30,505,701,481.00 | ₹262,043.00 |
Indoco Remedies Limited | INDOCO | ₹330.50 | ₹30,487,930,950.00 | ₹31,866.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹94.13 | ₹27,629,696,510.00 | ₹795,123.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1964
Gender: female
Year Born: 1975
Gender: Not Specified
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Aarti Pharmalabs Limited
The CEO is Hetal Gogri Gala.
The current price is ₹901.00.
The range is ₹551.05-949.5.
The market capitalization is ₹8,166.18 crores.
The dividend yield is 0.39%.
The P/E ratio is 30.00.
The company operates in the Healthcare sector.
Overview of Aarti Pharmalabs Limited (ISIN: INE0LRU01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹8,166.18 crores and an average daily volume of 436,343 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹3.5.